My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    APR-246 (PRIMA-1MET)
    APR-246 (PRIMA-1MET)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V2651
    CAS #: 5291-32-7Purity ≥98%

    Description: APR-246 (also known as PRIMA-1MET), a methylated derivative of PRIMA-1 and a mutant p53 reactivator, is a novel and potent small molecule compound that is able to restore wild-type conformation and function to mutant p53, and triggers apoptosis in tumor cells. It has the potential to treat various human tumor types that are mutant p53-dependent. PRIMA-1 suppressed the growth of Saos-2-His-273 osteosarcoma cell but did not affect the cell lines which express wild type P53. PRIMA-1 directly binds to mutant p53 according to gel shift assay. PRIMA-1MET induced nucleolar translocation of Hsp70, PML, CBP and p53 in MCF 7 cells. 

    References: Cell Death Dis. 2015 Jun 18;6:e1794; Clin Cancer Res. 2011 May 1;17(9):2830-41. 

    Related CAS:5608-24-2 (PRIMA-1) 

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)199.25 
    FormulaC10H17NO3 
    CAS No.5291-32-7  (PRIMA-1MET; APR-246); 
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: >10mg/mL 
    Water: <1 mg/mL
    Ethanol: <1 mg/mL
    SMILES O=C1C(COC)(CO)N2CCC1CC2
    Synonyms APR246; APR-246; APR 246; PRIMA-1Met.


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: APR-246 (PRIMA-1MET) is the first clinical-stage compound that reactivates mutant p53 and induces apoptosis. APR-246 is a prodrug that is converted to the active compound methylene quinuclidinone (MQ), a Michael acceptor that binds to cysteine residues in mutant p53 and restores its wild-type conformation. APR-246 completely restores the cisplatin and doxorubicin sensitivity to p53-mutant drug-resistant ovarian cancer cells. It not only reactivates p53 but also decreases intracellular glutathione levels in a dose-dependent manner. APR-246 can trigger apoptosis in a p53-independent manner by inducing ROS and endoplasmic reticulum (ER) stress and by inhibiting thioredoxin reductase 1 (TrxR1). It was also reported that APR-246 induces cell death in myeloma cells independently of p53 status by impairing the GSH/ROS balance. PRIMA-1Met/APR-246 efficiently inhibited the growth of the SCLC cell lines expressing mutant p53 in vitro and induced apoptosis, associated with increased fraction of cells with fragmented DNA, caspase-3 activation, PARP cleavage, Bax and Noxa upregulation and Bcl-2 downregulation in the cells.


    Kinase Assay: Cells are plated in six-well plates at a density of 15 000 cells per cm2. Next day, cells are treated with different concentrations of APR-246 (0, 25, 50, 75 and 100 μM) and harvested after 4, 12 and 24 h. The cells are lysed, and the clarified supernatants are used for either analysis of TrxR enzymatic activities or western blot. Total protein concentrations are determined with a Bradford reagent kit. Cellular TrxR activity is measured using an adapted Trx-dependent end point insulin reduction assay for microwell plates.


    Cell Assay: OVCAR-3 cells were plated at a density of 75 000 cells per well in 3 ml of medium in 12-well plates. Next day, 2.5 ml medium was removed and cells were treated with cisplatin or APR-246 or in combination for 20 h. Next day, cells were harvested by trypsinization, washed twice and cells were stained with Annexin V and propidium iodine (PI). After staining, the samples were analyzed by LSRII flow cytometer.

    In VivoAPR-246 showed a good safety profile in a Phase I/II clinical dose-finding study on hematological malignancies and prostate cancer and both clinical and p53-dependent biological responses were observed. In animal studies, APR-246 is well tolerated. Single treatment with APR-246 inhibits tumor growth by 21% in mice bearing the aggressively growing A2780-CP20 tumor xenografts 
    Animal modelCD-1 Nu/Nu mice  
    Formulation & DosageDissolved in PBS; 400 mg/kg/day; i.v. injection 
    ReferencesCell Death Dis. 2015 Jun 18;6:e1794; Clin Cancer Res. 2011 May 1;17(9):2830-41.  


    These protocols are for reference only. InvivoChem does not independently validate these methods.

     

    APR-246 (PRIMA-1MET)

    Inhibition of TrxR1 in vitro by APR-246.  2013 Oct 24;4:e881.

     

    APR-246 (PRIMA-1MET)

    siRNA knockdown of TrxR1 inhibits APR-246-induced cell death.  2013 Oct 24;4:e881.

     

    APR-246 (PRIMA-1MET)


    siRNA knockdown of TrxR1 inhibits generation of ROS induced by treatment with APR-246.  2013 Oct 24;4:e881.

     

    APR-246 (PRIMA-1MET)

    Inhibition of TrxR1 activity in living cells.  2013 Oct 24;4:e881.

     

    APR-246 (PRIMA-1MET)

     

    APR-246 (PRIMA-1MET)


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?